Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i).
1. A pharmaceutical composition that inhibits angiogenesis comprising SEQ ID NO: 3 as an active agent, and a pharmaceutically acceptable vehicle.
2. The pharmaceutical composition according to claim 1 , which contains about 0.001 mg to about. 50 mg of the active agent and is in a form capable of subcutaneous, intramuscular, intravenous or transdermal administration.
3. An isolated nucleic acid molecule comprising the nucleotide sequence SEQ ID NO: 3.
4. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 3 and a pharmaceutically acceptable vehicle.
5. A method of inhibiting angiogenesis comprising the step of administering to living cells the pharmaceutical composition of claim 4 .
6. The method of claim 5 , wherein a pathology linked to angiogenesis is treated.
7. The method of claim 6 , wherein the pathology linked to angiogenesis is selected from the group consisting of retinopathy, rheumatodi arthritis, Crohn's disease, atherosclerosis, hyperstimulation of the ovary, psoriasis, endometritis associated with neovascularization, restenosis due to balloon angioplasty, tissue superproduction due to cicaerization, peripheral vascular disease, hypertension, vascular inflammation, Raynaud's disease, Raynaud's phenomena, aneurysm, arterial restenosis, thrombophIebitis, lymphangitis, lymphedema, tissue cicatrization and repair, isehemia, angina, myocardial infarction, chronic heart disease, congestive heart failure, age-related macular degeneration andosteroporosis.